Boston Scientific names Fitzgerald COO. Boston Scientific stock gains 1.39 percent
Published on 10/07/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific (ISIN US1011371077) appointed Joseph M. Fitzgerald as executive vice president and chief operating officer effective January 1, 2027, while its stock traded at EUR 37.92 at Lang & Schwarz on October 7, 2026, up 1.39 percent versus the prior close of EUR 37.40. finanzen.ch reported the appointment on October 7, 2026. The leadership change also introduces a new operating structure from January 1, 2027.
Three segments from January 2027
Boston Scientific will organize its activities into Interventional Therapies, Rhythm Solutions and MedSurg. Fitzgerald will oversee global operations, business units and regions, with Lance Bates, Nick Spadea-Anello and Stephen Morse leading the three divisions, respectively, according to finanzen.ch on October 7, 2026. The structure separates cardiovascular, rhythm and surgical activities more clearly, giving investors a concrete operating milestone to track in 2027.
The company reported USD 5.44 billion of revenue in the second quarter of 2026, up 7.50 percent from the same quarter a year earlier. MarketBeat also reported adjusted earnings per share of USD 0.86 against a USD 0.83 consensus estimate for that quarter.
Analyst target reflects device pressure
Bernstein lowered its Boston Scientific price target from USD 60.00 to USD 54.00 on October 5, 2026, while maintaining an Outperform rating. Investing.com said the firm cited competitive pressure from Abbott Laboratories' Amulet 360 device against Boston Scientific's Watchman product. The report also cited Wells Fargo's USD 48.00 target after an estimated USD 300 million reduction in third-quarter sales linked to an eight-day operational disruption.
That contrast places the January reorganization beside a near-term execution test. Revenue growth remained positive in the second quarter, but the target reduction shows that investors are weighing competitive risk and distribution recovery against the company's operating scale.
Stock advances during October 7 trading
Boston Scientific was trading at EUR 37.92 at Lang & Schwarz on October 7, 2026 at 3:18 p.m. CEST, up 1.39 percent versus the EUR 37.40 prior close from October 6, 2026. The primary listing is on the NYSE, where the finance quote showed a USD 62.7 billion market capitalization and a USD 41.94 to USD 105.65 52-week range as of October 6, 2026.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- WKN: 884113
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 7, 2026 at 3:18 p.m. CEST: EUR 37.92
- Change versus prior close: plus 1.39 percent
- Prior close Lang & Schwarz October 6, 2026: EUR 37.40
- Market capitalization: USD 62.7 billion as of October 6, 2026
- 52-week range: USD 41.94-105.65 as of October 6, 2026
- Sector / Industry: Healthcare / Medical Devices
